Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA‐B) genotype and allopurinol dosing: 2015 update

von Saito, Y, Stamp, LK, Caudle, KE, Hershfield, MS, McDonagh, EM, Callaghan, JT, Tassaneeyakul, W, Mushiroda, T, Kamatani, N, Goldspiel, BR, Phillips, EJ, Klein, TE, Lee, MTM
Veröffentlicht in Clin Pharmacol Ther (2016)

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing

von Johnson, JA, Gong, L, Whirl-Carrillo, M, Gage, BF, Scott, SA, Stein, CM, Anderson, JL, Kimmel, SE, Lee, MTM, Pirmohamed, M, Wadelius, M, Klein, TE, Altman, RB
Veröffentlicht 2011

Impact of the CYP4F2 p.V433M Polymorphism on Coumarin Dose Requirement: Systematic Review and Meta-Analysis

von Danese, E, Montagnana, M, Johnson, JA, Rettie, AE, Zambon, CF, Lubitz, SA, Suarez-Kurtz, G, Cavallari, LH, Zhao, L, Huang, M, Nakamura, Y, Mushiroda, T, Kringen, MK, Borgiani, P, Ciccacci, C, Au, NT, Langaee, T, Siguret, V, Loriot, MA, Sagreiya, H, Altman, RB, Shahin, MHA, Scott, SA, Khalifa, SI, Chowbay, B, Suriapranata, IM, Teichert, M, Stricker, BH, Taljaard, M, Botton, MR, Zhang, JE, Pirmohamed, M, Zhang, X, Carlquist, JF, Horne, BD, Lee, MTM, Pengo, V, Guidi, GC, Minuz, P, Fava, C
Veröffentlicht 2012